ArticleClinicoEconomics and outcomes research : CEOR2026
The Early Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients with Early Breast Cancer.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy-induced alopecia is a common side effect with psychological impacts that affect quality of life. Up to 14% of patients may decline chemotherapy due to concerns over hair loss. While existing scalp cooling therapies can reduce alopecia, constraints including space, staffing, and extended chair time limit their use in health services. Hence, a novel scalp cooling cap ("Product X") was developed to address this gap. Product X is cordless and portable and does not require patients to remain in treatment chairs post-chemotherapy. This early-stage cost-effectiveness analysis addresses the potential economic value of adopting Product X versus current practice (no scalp cooling). Methods: We developed a decision tree and a lifetime Markov model to estimate change to total costs and health benefits for female patients with early breast cancer, from a health system perspective in a Singapore tertiary cancer care setting. The model incorporated costs related to scalp cooling equipment and administration, chemotherapy, and treatment for cancer recurrence. Assumptions regarding Product X's efficacy and its potential impact on chemotherapy compliance were tested in nine scenario analyses (efficacy: 50%, 75%, 100%; compliance improvement: 0, 1%, 5%). Probabilistic scenario analysis was conducted using Monte Carlo simulation with 1000 iterations from appropriate parameter distributions. Results: In the base case (1% improvement in compliance and 100% efficacy), Product X yielded an incremental cost of S$265 per patient (95% UI: S$251-S$281) and incremental quality-adjusted life years (QALY) of 0.0717 (95% UI: 0.0705-0.0729). At a willingness-to-pay of S$45,000 per QALY, incremental net monetary benefits (INMB) was S$2961 (95% UI: S$2906-S$3015), with >99.9% probability of cost-effectiveness. Across all scenarios, INMB ranged from S$1158 to S$3330. Conclusion: Scenario and probabilistic analyses suggest that Product X is a cost-effective solution for chemotherapy-induced alopecia, supporting its adoption from a health system perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.